ClinicalTrials.gg
CompletedNCT06081621Updated Mar 18, 2026

A Clinical Study to Evaluate the Efficacy and Safety of REGEND001 Cell Therapy on Idiopathic Pulmonary Fibrosis (IPF)

A Phase 2 interventional study of REGEND001 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Regend Therapeutics. Completed at 4 sites in China. Open to participants aged 40 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Regend Therapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
23
Allocation
Randomized
Ages
40 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China — 25 open to participants now, 29 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · China.

Enrollment
49th of 60
23 · median 83
Started
2023
with 7 others
Phase 2
21 of 67
7 open now
Registered
31st of 67
by date
Lead sponsor
3 of 67
Regend Therapeutics

Among the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, this one is the 49th largest by enrollment of the 60 interventional ones that give a count, is one of 8 that started in 2023, is one of 21 in phase 2, and was the 31st registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

25 of the 67 studies in Idiopathic Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies in Idiopathic Pulmonary Fibrosis with a site in China, or all of them as a file.
02

Study summary

Idiopathic pulmonary fibrosis (IPF) is a serious chronic (long term) disease with injury of lung tissues. REGEND001 is a cell therapy product, made from bronchial basal cells with ability to regenerate lung tissue, is promising to IPF treatment. This is a multi-center, randomized, double-blinded, parallel and placebo-controlled phase II clinical study to evaluate the efficacy and safety of REGEND001 in IPF patients.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis
04

Who can participate

Ages eligible
40 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female, aged between 40 to 75;
  • Subjects diagnosed with IPF according to guidelines for the diagnosis of idiopathic pulmonary fibrosis 2022 edition;
  • Subjects with DLCO (measured/predicted value) ≥30% and \<80%, and FVC (measured/predicted value) ≥50% within 3 months prior to screening
  • Subjects tolerant to bronchofiberscope;
  • Subjects tolerant to test of lung function;
  • Subjects able to voluntarily sign the and cooperate with the completion of pulmonary function tests;

Exclusion criteria

Exclusion Criteria:

  • Female subject who is pregnant, nursing, or planning to be pregnant in half a year after using this product (or male subjects planning to have a pregnant spouse);
  • At the time of screening, subject who is positive in each of treponema pallidum antibody (TP-Ab), (HIV) antibody, surface antigen (HBsAg), virus (HCV) antibody test, except the following: (1) Hepatitis B virus carriers (only HBsAg positive, no hepatitis symptoms and signs, all liver function tests are normal); (2) Cured hepatitis C patients with negative result in HCV ribonucleic acid (RNA) test.
  • Subject with malignant tumors or a history of malignant tumors;
  • Subject with severe anemia, poorly controlled agranulocytosis and thrombocytopenia at screening;
  • Subject at risk of suicide or has a history of mental illness or epilepsy at the time of screening;
  • Subject with severe arrhythmias or atrioventricular block of degree II or above, shown by 12-lead (ECG);
  • Subject who participated in other interventional clinical trials in the past 3 months;
  • Subject assessed as inappropriate to participate in this clinical trial by investigators.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
23 participants (actual)

Study arms

  • Experimental
    REGEND001

    Biological: REGEND001

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalREGEND001

    REGEND001: 1-1.5×10\^6 bronchial basal cells/kg administrated by bronchoscopy.

  • BiologicalPlacebo

    Placebo: Sodium chloride injection administrated by bronchoscopy.

06

What researchers measure

Primary outcomes

  1. Comparison of the area under the curve (AUC) of DLCO measured values at each visit from baseline to week 24 between the REGEND001 group and the placebo group.

    DLCO is measured by the single-breath method. Improvement is defined as an increase in DLCO from baseline.

    Time frame: 12 and 24 weeks after treatment

Secondary outcomes

  1. Change from baseline in lung diffusing capacity

    DLCO will be used to evaluate the lung diffusing capacity. DLCO test refers to the diffusing capacity for carbon monoxide in the lungs. It's a type of pulmonary function test that helps to assess how well gas is exchanged between the lungs and the bloodstream.

    Time frame: 12 and 24 weeks after treatment

Other outcomes

  1. Change from baseline in lung ventilatory capacity

    Forced vital capacity (FVC) and forced expiratory volume in one second (FEV1) will be used to evaluate the lung ventilatory capacity. FVC indicates the volume of air that can forcibly be blown out after full inspiration. FEV1 is the volume of breath exhaled with effort in one second.

    Time frame: 12 and 24 weeks after treatment

  2. Progression-free survival (PFS)

    PFS refers to the time from randomization or initiation of treatment to the occurrence of disease progression or death.

    Time frame: Within 24 weeks after treatment

  3. Change from baseline in St. George's respiratory questionnaire (SGRQ) scale

    Quality of life was assessed by St. George's respiratory questionnaire (SGRQ) scale. Total score, ranged from 0 to 100, is the sum of points from all items. A higher value represents a worse outcome.

    Time frame: 12 and 24 weeks after treatment

  4. Change from baseline in 6-minute-walk test (6MWT)

    The 6MWT is a commonly used test for the objective assessment of functional exercise capacity by testing the distance patients can walk at the fastest speed within 6 minutes.

    Time frame: 12 and 24 weeks after treatment

  5. Time from enrollment to all-cause death

    Time from enrollment to all-cause death is used to evaluate the overall survival of the population.

    Time frame: up to 24 weeks(first period), 5 years (second period).

  6. Blood oxygen saturation

    Blood oxygen saturation is the measure of how much oxygen is traveling through body in red blood cells.

    Time frame: 12 and 24 weeks after treatment

  7. Change from baseline in images of lung by high resolution computed tomography (HR-CT)

    HR-CT images of lung will be analyzed to indicate the change of pulmonary structure.

    Time frame: 12 and 24 weeks after treatment

  8. Change from baseline in C-reactive protein (CRP)

    The level of CRP increases when there's inflammation in the body.

    Time frame: 12 and 24 weeks after treatment

  9. Time to acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF)

    AE-IPF is an often deadly complication of IPF, which is defined as an acute, clinically significant respiratory deterioration characterized by evidence of new widespread alveolar abnormality.

    Time frame: Within 24 weeks after treatment

  10. Temperature

    Number of cases with abnormal body temperature.

    Time frame: Within 24 weeks after treatment

  11. Breathing

    Number of cases with abnormal breathing.

    Time frame: Within 24 weeks after treatment

  12. Pulse

    Number of cases with abnormal pulse.

    Time frame: Within 24 weeks after treatment

  13. Blood pressure

    Number of cases with abnormal blood pressure.

    Time frame: Within 24 weeks after treatment

  14. Symptoms, physical examination

    Number of cases with abnormal physical examination

    Time frame: Within 24 weeks after treatment

  15. 12-lead ECG

    Number of cases with abnormal 12-lead Electrocardiogram (ECG).

    Time frame: Within 24 weeks after treatment

  16. Blood routine

    Number of cases with abnormal laboratory test results

    Time frame: Within 24 weeks after treatment

  17. Liver & Kidney function check

    Number of cases with abnormal results in Liver \& Kidney function check

    Time frame: Within 24 weeks after treatment

  18. Blood glucose

    Number of cases with abnormal results

    Time frame: Within 24 weeks after treatment

  19. Function of blood clotting

    Number of cases with abnormal function of blood clotting.

    Time frame: Within 24 weeks after treatment

  20. Antibody testing for autoimmune diseases

    Antibodies related to autoimmune diseases are tested for safety assessment

    Time frame: Within 24 weeks after treatment

  21. Carcinoembryonic antigen (CEA)

    CEA is a tumor marker used for early diagnosis of lung cancer.Clinically significant changes of this markers will be assessed.

    Time frame: Within 24 weeks after treatment

  22. Neuron-specific enolase (NSE)

    NSE is a tumor marker significantly elevated in small cell lung cancer. Clinically significant changes of this marker will be assessed

    Time frame: Within 24 weeks after treatment

  23. Cytokeratin-19-fragment (CYFRA21-1)

    CYFRA21-1 is a tumor marker which is valuable for the pathological classification and prognosis evaluation of lung cancer. Clinically significant changes of this marker will be assessed

    Time frame: Within 24 weeks after treatment

  24. Squamous cell carcinoma antigen (SCC)

    SCC is a specific marker for lung squamous cell carcinoma. Clinically significant changes of this marker will be assessed

    Time frame: Within 24 weeks after treatment

  25. Other cases of adverse effects

    Other cases of adverse effects will be recorded and compared.

    Time frame: Within 24 weeks after treatment

07

Study locations

4 sites
  • Peking Union Medical College Hospital, Chinese Academy of Medical Sciences
    Beijing, Beijing Municipality, China
  • The Second Affiliated Hospital of Xiamen Medical College
    Xiamen, Fujian 361021, China
  • Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
    Shanghai, Shanghai Municipality 200025, China
  • Renji Hospital, Shanghai Jiaotong University School Of Medicine
    Shanghai, Shanghai Municipality 200127, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2023 to primary completion in Mar 2025, 15 months.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 15 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2023
First posted
Oct 13, 2023
StartActual
Dec 11, 2023
Primary completionActual
Mar 14, 2025
CompletionActual
Mar 14, 2025
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06081621
Lead sponsor
Regend Therapeutics
Collaborators
Peking Union Medical College Hospital, RenJi Hospital, Ruijin Hospital, Second Affiliated Hospital of Xiamen Medical College
Responsible party
Sponsor
First posted
Oct 13, 2023
Start date
Dec 11, 2023
Primary completion
Mar 14, 2025
Completion
Mar 14, 2025
Last update
Mar 18, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: REGEND001

Start the discussion